四价登革热疫苗一剂与两剂方案在2-17岁儿童中的免疫原性和安全性:18个月中期数据
这项2期随机双盲安慰剂对照研究在多米尼加共和国、巴拿马和菲律宾的1800名2-17岁儿童中评估Takeda四价登革热疫苗(TDV)不同剂次方案的免疫原性和安全性。18个月中期数据显示,所有TDV组抗体滴度在接种后18个月仍保持升高,组1和组2(分别接种两剂和一剂)间GMT差异有限;在基线血清阴性者中,1年后加强针明显提高GMT。TDV耐受良好,对全部四种登革血清型均有免疫原性,无论基线登革血清状态如何。
要点
- TDV对四种登革血清型均具免疫原性,抗体滴度维持至18个月。
- 两剂与一剂方案间GMT差异有限,基线血清阴性者加强针明显提高GMT。
- 疫苗相关非征集不良事件发生率为2%(14/562),无疫苗相关严重不良事件。
核心结论
- TDV耐受良好,对全部四种登革血清型均有免疫原性,无论基线登革血清状态如何。
- 这些数据为TDV提供了概念验证,并支持正在进行的间隔3个月两剂方案的3期效力评估。
研究设计与样本
- 2期、多中心、随机、双盲、安慰剂对照研究,在多米尼加共和国、巴拿马和菲律宾三个中心开展。
- 2014年12月5日至2015年2月13日随机分配1800名2-17岁儿童至组1(n=201)、组2(n=398)、组3(n=1002)和组4(n=199),随机比1:2:5:1,按年龄分层。
- 1794名参与者接受至少一剂TDV或安慰剂(安全性集),其中562名参与免疫原性子集,509名纳入符合方案集。
- 18个月中期分析主要终点为符合方案免疫原性子集在第1、28、91、180、365、393和540天的登革血清型特异性抗体几何平均滴度(GMT)。
主要发现
- 第540天,组1、2、3、4的DENV-1 GMT分别为476(95%CI 286-791)、461(329-647)、1056(804-1388)、92(49-173)。
- 第540天,组1、2、3、4的DENV-2 GMT分别为1212(842-1744)、1242(947-1628)、1457(1182-1796)、177(93-337)。
- 第540天,组1、2、3、4的DENV-3 GMT分别为286(171-478)、298(205-433)、548(411-730)、78(44-137)。
- 第540天,组1、2、3、4的DENV-4 GMT分别为98(65-150)、102(75-139)、172(133-222)、33(21-52)。
关键数值与推荐
- 组1和组2(分别接种一剂和两剂TDV)间观察到GMT差异有限。
- 在基线血清阴性参与者中,1年后加强针明显增加GMT。
临床怎么用
- TDV在2-17岁儿童中耐受良好且对四种登革血清型均具免疫原性,支持间隔3个月两剂方案的3期效力评估。
- 基线血清阴性者接种1年后加强针可明显提高抗体滴度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Development of vaccines that are effective against all four dengue virus serotypes (DENV-1-4) in all age groups is important. Here, we present 18-month interim data from an ongoing study undertaken to assess the immunogenicity and safety of Takeda's tetravalent dengue vaccine (TDV) candidate over 48 months in children living in dengue-endemic countries. METHODS: We undertook a phase 2, multicentre, randomised, double-blind, placebo-controlled study at three sites in the Dominican Republic, Panama, and the Philippines. We randomly assigned children aged 2-17 years to receive either two TDV doses 3 months apart (group 1), one TDV dose (group 2), one TDV dose and a booster dose 1 year later (group 3), or placebo (group 4). We did the randomisation (1:2:5:1) using an interactive web response system stratified by age. The primary endpoint of this 18-month interim analysis was DENV serotype-specific antibody geometric mean titres (GMTs) in the per-protocol immunogenicity subset on days 1, 28, 91, 180, 365, 393, and 540. Secondary safety endpoints were the proportions of participants with serious adverse events and with virologically confirmed dengue in the safety set, and solicited and unsolicited adverse events in the immunogenicity subset. This trial is registered with ClinicalTrials.gov, number NCT02302066. FINDINGS: Between Dec 5, 2014, and Feb 13, 2015, 1800 children were randomly assigned to group 1 (n=201), group 2 (n=398), group 3 (n=1002), and group 4 (n=199). 1794 participants received at least one dose of TDV or placebo (safety set), of whom 562 participated in the immunogenicity subset and 509 were included in the per-protocol set. Antibody titres remained elevated 18 months after vaccination in all TDV groups. At day 540, in groups 1, 2, 3, and 4, respectively, DENV-1 GMTs were 476 (95% CI 286-791), 461 (329-647), 1056 (804-1388), and 92 (49-173); DENV-2 GMTs were 1212 (842-1744), 1242 (947-1628), 1457 (1182-1796), and 177 (93-337); DENV-3 GMTs were 286 (171-478), 298 (205-433), 548 (411-730), and 78 (44-137); and DENV-4 GMTs were 98 (65-150), 102 (75-139), 172 (133-222), and 33 (21-52). Limited differences in GMTs were observed between groups 1 and 2 (in which participants received one and two doses of TDV, respectively). In baseline-seronegative participants, a 1-year booster clearly increased GMTs. Vaccine-related unsolicited adverse events occurred in 14 (2%) of 562 participants, but no vaccine-related serious adverse events arose. Symptomatic, virologically confirmed dengue was recorded in 21 (1·3%) of 1596 participants vaccinated with TDV compared with nine (4·5%) of 198 placebo recipients. INTERPRETATION: TDV was well tolerated and immunogenic against all four dengue serotypes, irrespective of baseline dengue serostatus. These data provide proof of concept for TDV and support the ongoing phase 3 efficacy assessment of two doses 3 months apart. FUNDING: Takeda Vaccines.
引用
- Sáez-Llorens X, Tricou V, Yu D, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2017. PMID: 29122463. doi:10.1016/S1473-3099(17)30632-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。